Fever Breaking For Momentum Stocks… And Sarepta Surges After FDA Approval 6/21/24

21 Jun 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Episode Notes: CNBC's "Fast Money" - Fever Breaking For Momentum Stocks… And Sarepta Surges After FDA Approval (6/21/24)

Episode Overview

  • Hosts: Melissa Lee with traders Tim Seymour, Karen Feinerman, Bonoan Eisen, and Steve Grasso.
  • Main Topics:
  • The performance of high-momentum stocks like NVIDIA, Chipotle, and Costco.
  • Analyst ratings and expectations for Nike.
  • Upcoming earnings reports for FedEx and Micron.
  • A deep dive into the cryptocurrency market, particularly Bitcoin.
  • A significant surge in Sarepta Therapeutics following FDA approval for its muscular dystrophy drug.

---

Key Discussions

High-Momentum Stocks Performance

  • NVIDIA:
  • Recently hit an all-time high but has seen a 10% decline since.
  • Analysts and traders debated whether this decline is a minor setback ("molehill") or indicative of larger issues in the bull market ("mountain").
  • Tim Seymour noted the need for broader market participation beyond just a few stocks.
  • Other Stocks:
  • Chipotle and Costco also reported pullbacks from recent highs, suggesting a broader trend affecting previously high-flying stocks.
  • The consensus among traders is that while these declines may seem alarming, they could be healthy corrections.

Analyst Insights on Nike

  • Oppenheimer upgraded Nike to "outperform," citing a potential rebound.
  • However, traders expressed skepticism regarding the absence of clear catalysts for growth.
  • Discussion focused on Nike's competitive landscape against brands like Hoka and On, with concerns about market share.

Earnings Outlook

  • FedEx and Micron:
  • Anticipation builds as earnings reports for these companies loom next week.
  • Concerns were raised about FedEx's reliance on cost-cutting rather than organic growth.

Cryptocurrency Market Update

  • Bitcoin and related stocks faced pressure, with discussions around the future of crypto markets.
  • Concerns about the halving event and regulatory updates impacting investor sentiment.

Sarepta Therapeutics Surge

  • FDA Approval:
  • Sarepta Therapeutics' muscular dystrophy drug received expanded FDA approval, causing a 30% stock surge.
  • CEO Doug Ingram discussed the potential for increased sales, estimating a possible rise from $2.5 billion to $4 billion.
  • Concerns were raised about the drug's controversial approval process and its potential impact on payer acceptance.

---

Key Takeaways

  • The recent pullbacks in high-momentum stocks are viewed by some traders as healthy corrections that could pave the way for broader market participation.
  • Analysts express mixed feelings about Nike's upgrade, highlighting a lack of compelling catalysts for growth.
  • Upcoming earnings reports for major companies like FedEx and Micron will be critical to monitor, given current market conditions.
  • Sarepta's FDA approval signifies a transformative moment for the company, yet the implications of its approval process remain a concern for future sales.
  • The cryptocurrency market is experiencing volatility influenced by both market sentiment and regulatory developments.

---

Final Thoughts The discussions on "Fast Money" reflect a cautious optimism in the market, signaling that while certain high-momentum stocks are experiencing pullbacks, the overall sentiment remains focused on long-term growth potential. Traders are advised to stay vigilant as earnings reports and market trends unfold. The episode underscores the importance of evaluating both technical indicators and broader market dynamics when making investment decisions.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:03Live from the Nasdaq market site in the heart of New York City's Times Square. This is Fast money. Here's what's on tap tonight. Wilting in the summer heat? We all are. Well, this week, some of the market's hottest momentum stocks, NVIDIA, Chipotle and Costco, started to lose a little of their mojo. Is this a bad sign for the health of the bull market? We'll debate that. Plus, swooshing higher. A bull call today from an analyst on Nike. Our traders set to weigh in on why they aren't buying what he is selling. And later, gearing up for results from FedEx and Micron, a rough end of the week for the big banks.

0:33And what is behind the beating Bitcoins taking right now. I'm Melissa Lee. Come to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Karen Feinerman, Bono and Eisen, Steve Grasso. I'm not losing my voice. Not a Peter Brady moment. But you've been on the network. This is your third hour today. Yes. That's an aside. We start off with a handful of high-momentum stocks suffering a little heat stroke in the hot summer sun. Nvidia, the obvious example, hitting an all-time high yesterday morning and now down 10 percent since then. That technically puts it in correction territory.

1:04and drops it back to the number three spot on the market cap leaderboard. But NVIDIA is not the only stock following that pattern. Chipotle is down more than 7 % from its Tuesday record and now negative for the week. Eli Lilly and Costco also pulling back from their best levels hit just in the last few days. So there's a fever breaking after these stocks' massive run. We asked last night, mountain out of a molehill. We did see follow-through action today. So molehill still, Tim, or mountain? Or maybe somewhere in between? Apparently, I gave too much information about moles, but I was actually referring to the varmints that live in my yard.

1:40Again, and the question was posed whether this is good or bad for the bull market. Isn't this good? I mean, don't we want to see these runaway trains actually slow down a little bit and start to broaden? Now, it doesn't mean they will broaden, but the parabolic move in NVIDIA is something that I think has a lot of people uncomfortable. The fact that depending on which surveys you're looking at and there's different graphs that look at momentum. The fund manager survey of Bank of America was out this week. I participate in that. It's clearly as overweight equities as it's been in some time or at least near a range where it's near that level.

2:13So I look at where the participation of look, we want to see transports. We want to see industrials. They've actually been under some pressure. We've talked about sectors that don't really seem to matter like industrials. sorry, excuse me, like energy, industrials do matter, like energy, like utilities, so to speak, to the to the more broad market. I actually think that this week was interesting because on top of what we had in terms of maybe these blow off tops for at least some period, is that we've had economic data that continues to show that I think the economy is slowing a little bit. And that's the part of this that's the most interesting to me, because I don't think the market wants to see a lot of that.

2:48But everything else in terms of the price action, look, we were due for this. I am not going to go into the weekend and say this is the beginning of a major pullback. I tend to agree. I tend to agree. I don't think this is definitely a mountain either. And I'm with Tim, I would say, 99 % of the way. We do want to see that breadth. I'm not necessarily convinced that we're set up to see that breadth, however. If you really look at earnings growth, what we've seen over the last year, I would actually purport the last two years, it's really been concentrated in, call it, 5 to 15 names. And I'm not sure that the balance of stocks in the S &P really have what it takes to kind of fill in the gap from an earnings growth standpoint.

3:28That doesn't mean that we can't continue to rally. But now we're predicated on having a PE expansion. And I think this late in the cycle, expecting to see that multiple expand with more stagnant earnings growth, I think that might set up to be a bit more troublesome. I agree with you very much on the on the PE multiple being part of the driver. It has to be earnings. It has to be a beat. The bar is already so high, though. That's the problem. And, I mean, you know, if we look at the chart and squint, they haven't even really topped. They're back to, like, where they were Wednesday or Tuesday of last week.

3:59But that feeling of sort of frothiness that was there, was it just yesterday morning? Yesterday morning. Yes, with NVIDIA hitting a new high. Yes, hitting a new high. I don't know. That just seemed like we just have to be in it, like a panic buying kind of, you know, we've got to be in this name. And so a 10 % pullback is actually nothing in this. I wouldn't actually be surprised if it did a further pullback, which still would be warranted, I think. And I know Tim was saying yesterday, tons of buyers who want to buy it down, I don't know, 20 % from that? 10%. You've got 10 % on here. 115 is a level on the charts that I think people would love to buy NVIDIA, and I think they will.

4:37Yeah. I was talking to Santoli this morning on Squawk on the Street, and he referenced the outside reversal day back in March, which Guy talked about last night. If you pull up that chart, what happened after that outside reversal day? We had a breather, right? I mean, that came in at$200. But that was a buying opportunity. It was a buying opportunity. And as long as they hold 80, 85 % share in AI, all of these sell-offs are going to be buying opportunities. I feel like you started a new game, Mountain or Mole Hill. So I think it'll be Mole Hill. Just because I use the word or doesn't mean I'm setting up for a game.

5:07I get excited for games. Friday, it's a game. So I'll play the game. So I'll play my game. So I think it's a molehill on all of these. And to Karen's point, as she said, if you squint, these things are right where they were. Lilly is the holy grail. It seems like the holy grail right now. Chipotle, they're splitting next week. Tuesday, I believe it is, right? 50 for one. So you're going to see a little bit. Maybe you get a better entry level here if you are not included. The day of record was the 18th. Does anyone think that you're not going to see international growth out of Chipotle? I don't think so.

5:44So is it factored in? Definitely not. Mole Hill. Mole Hill. Costco. Renewal rate, 90%. Mole Hill. This is going to be for them. All these fundamentals, which are great. It doesn't mean that these stocks are not overvalued, though. Well, overvalued is speculative on a daily basis. It could be overvalued or undervalued. When we were looking at NVIDIA, there were analysts that thought when NVIDIA was trading at$900, that$1 ,350, when that was, oh, my gosh, that's so high that the stock would still be cheap. And it turned out that it still was cheap. So are you going to see these pullbacks? Yes. Are they still on?

6:21NVIDIA is on that mountain with a molehill on its feet, conflating here. A molehill on its feet. Just a little bit. Go with me here. Go with me here. Twin Peaks. Thank you. So if you think that, as I said before, they're so far ahead of everybody else. There's other ways to make money in AI. but until further notice, NVIDIA is still the king. Would it buy lower by 11 bucks or so? Maybe, yeah. I mean, I think the valuation is defendable. I think if I look at the charts, and I certainly think there's a context for where you want to leg into trades. If you want to own this market long-term, you're looking for that opportunity to buy it.

6:59So for clients I have that want to own NVIDIA, I feel like they've left out. I mean, you're going to start to leg in the trade. They want to own the market. Question is, you know, where do you want to be underweight or overweight and how much you actually want to get there? The fact that, look, NVIDIA, even after a heroic run over the last two years, in April gave you an opportunity to buy it down, you know, at$65 or$70. I mean, so the question is, how do you want to tactically get to the place you want to be in terms of your position size? I would just say that this week was also very interesting because you saw the NASDAQ, you know, kind of reassert itself in terms of fresh relative outperformance to the S &P.

7:34The NASDAQ hadn't done that. We talk about semis all the time. They had done that. But the Nasdaq jumped back into that phrase. So I look at, again, the market that we had this week. And I think there's a fly like the talk of wildlife here. Anyway, I sorry. I keep getting buzzed by a fly in the studio. It's tough. I think we have a case here where there's nothing that happened this week that isn't surprising. And there's nothing that happened this week when you consider where the positioning in the market is. This pullback to me is very healthy. It's not even a pullback. I mean, we're talking about 18 hours of price movements, really, or 36 hours.

8:09It's really, it's the peak of yesterday and today's session. And I understand outside reversals can be powerful. But I'm just, the only reason we're having this conversation is because the move was so extraordinary to the upside. And it was 13 days in a row we saw NVIDIA go higher, and we just kept coming in every day. And the fact that it's not, and it's given a little bit back. And we also haven't had a 2 % sell-off in how many days? 333 days in the S &P. So this is a long time coming and people are waiting for it. So we're hypersensitive when we're going to get the crack. As a trader, you don't ever think that you're right when you make that first purchase.

8:45You always say that's why you don't buy 100 percent of your position the first day. You actually get accustomed to hoping that you're wrong with that first purchase, whether you're dividing it up in 20 percent lots or a third. So if you're haggling over NVIDIA, whether it's a great buy at$126 or you're waiting for$115, just buy it. Just buy 20 % of your position and hope you're wrong. Not to mention that today is we've had rebalancing. We've had option X3. We've had futures X3. There are definitely things under the surface that have nothing to do with valuation, why you're having buy and sales and perhaps mismatches.

9:19Do you think that expiration is contributing to this decline that we've seen in NVIDIA, though, or these momentum stocks in general? I don't think that it's immaterial. OK, sure. I think there's an argument to be said. Listen, and I've always said this. You should expect some volatility in something that has I don't know exactly what the beta is, but I would argue probably 175, maybe even north of two. So you're expecting this. What I'm saying is that when you have positions roll off, maybe I don't know how many of the options expired in or out of the money today specifically. But that coupled with the rebalancing and all of that buying momentum that you had by the XOK going into the print today, it wouldn't make sense that perhaps it takes a bit of a breather.

9:58I see 167 as the beta, but they're partially responsible for part of the beta. I feel like, you know, but I very much agree with Steve's point. You never you you want to be wrong at the beginning when you buy something. And I kind of want to be wrong for having sold some and want to from NVIDIA and having, you know, want to be wrong for buying puts. Were you looking to sell any more today? I was not. You were not. I had my puts. I sold some calls and I sold some stock. And now I feel like, all right, I still have a lot of exposure to the space between Dell, Amazon, Meta, Google. Right. It's a big position also.

10:32So sticking where I am. And I just get back to where I think you could pull back to. It's great we're about to have Carter come on the show because this is what he does really well. But you could look at the semiconductors or the SMH, the ETF that tracks that. You could see that pull all the way back to 240. and that would be another, I don't know, 10 % from here, and you'd still be holding that uptrend, and that's an uptrend that's from October of last year. One more thing, because we give a lot of useful information on this show. Moles are less dangerous than voles. And I have voles in my yard, too.

11:02Moles are just eating grubs. Moles are less dangerous than what? Voles. What's a vole? There's a difference. It's a terrible-looking rodent, and it's blind. Yes, it appears to have what were eye sockets or something, but they don't have eyes. We do have to remind ourselves that we're on air. But Volzee plants. We're not a break. So they could take down a very mature rhododendron, for example, and you won't even know it until it's too late. Be careful out there. I don't know if it's useful or not. It's very useful. Let's bring in Carter Braxton Wirth, the chart master, to tackle whether these stocks have in fact lost their mojo.

11:39Carter, what do you see? I'm stuck on rhododendron. But so, yeah, I mean, look, we can't call it a dip to make the ball. Nothing happened. Right. I mean, you're talking about most sectors are up this week. Tech, of course, one of the ones that was down, but almost every sector up at some point. We are all waiting. Right. When does this is sort of getting to be parabolic, over love, crowded, expensive run pause. But I will point out that if you look at the top five largest holdings, we'll get to some charts in a second. in the momentum ETF, three of them were down for the week. But anyway, we know that the breath is terrible.

12:18And this has been the case. You know, even the Nasdaq 100, the equal weight Nasdaq 100 has not made a new high. But these are the top five holdings in the iShares momentum ETF. And in fact, NVIDIA was down for the week. Vago was down. Meta was down. But the one that really jumps out and we'll look at some charts is meta. But first, let's look at a few charts relating to this ETF compared to the market and compared to other aggregates. But meta of all of these, it peaked on the 8th of April. Every other stock, the top five, made a new 52-week high this week. And so meta is the one that I would say.

13:02Looking at semis, certain semis have been struggling for months, right? AMD, for instance. And so just a quick reversal on MU or Nvidia, that's sort of day-to-day stuff. But meta is about to break trend here to my eye. And worse is its relative performance, I think it's the final chart we have, to the momentum ETF. So now you're getting into some autocorrelation, but it's a pure exercise. It's one of the parts juxtaposed against the whole meta relative to the iShares momentum. And it is already broken trend. This is the one that I would say keep an eye on. We know that Salesforce is cracked, Intuit is cracked, but this is a lot bigger name.

13:44And any further weakness from here will start to mean something. I almost feel stupid. We've been focusing on NVIDIA and Broadcom for so much of the show. And you're saying, take a look at meta. That's the one in danger. But Carter, you know, in terms of reversals and how reversals go, don't they signify something in the charts or no? Do you just not really? Sure. I mean, down one day, I mean, let's say, again, it's at 18 hours or something. If a stock has gone up 30, 40, 50 percent in the course of several weeks, it's entitled to drop one, two, three, four, five, not to personify the stock. But what NVIDIA has done is nothing.

14:21Now, can it turn into a route? Maybe it crashes Monday. But the point is, we can't come to that judgment. At least I can. If any of you can, I would say I'll come work for you. But the point is, yes, I see the cracks. The semis were the most steep, most loved. So they're the ones that sort of got hurt today. But one can't impute from this small bit of data further downside, other than to say they should all be a lot lower in the sense that they're all over-owned, overbought and, I think, over-loved. So does that mean that you would not recommend buying them? And I guess I'm asking, is the uptrend intact still, even if we see, you know, dips here?

15:02We're speaking of the market or NVIDIA? No, NVIDIA for semis. Yeah, for semis. Yeah, the break, remember, you have to put in the context of the breakout, right? Semis were range-bound, and then they broke out, NVIDIA being the big contributor. And now you have a two-day give-back. You wouldn't even call it a dip or a sell-off or certainly not a correction or a drawdown. A two-day giveback in the context of something that just broke out. I would say you surely should get more than just two days. But how much more before it becomes an opportunity? I wouldn't read all that much into it. All right.

15:35Carter, thank you. Carter Braxton Worth of Worth Charting. Karen, are you worried about your meta now that Carter's alerted us to the break in trend happening? Yeah, I mean, you know, I like Carter's work, so I don't love it when he has something that he feels, you know, is destined to trade down. But I just look at the Meta valuation and I look at the NVIDIA valuation or some of the other ones, even Amazon, Microsoft. It's a different stratosphere kind of. Some of the NVIDIA stratosphere is much higher. But so Meta at 24 times earnings, and that doesn't include the cash. I don't feel like there's a tremendous amount of downside.

16:12I want to own it right here. I've not sold any. All right. Let's dive deeper into the drop in NVIDIA, specifically the AI Darling closing out its first down week since mid-April after two days of losses. But options traders are still piling in on the bullish bets. Mike Coe has the action. Mike? Yeah. I mean, this one is, of course, the busiest single stock option by a good margin. It actually traded over 8 million contracts today, which exceeded even the number of contracts that spy the ETF, which is usually the busiest contract traded. We did see calls outpacing puts, though, by about 5 to 3.

16:44And if we exclude those contracts which expire today, the busiest contracts all expiring next week were the 130, 135, and 140 strike calls. The 130 has traded almost 180 ,000 contracts. Buyers were paying a little over$2.90 a contract for those. It is worth pointing out, though, that some of that could be a substitution. You could see some people who are deciding that they're going to take profits on their shares and buy a little bit of upside just in case it actually regains its mojo. Mike, thank you. Mike Coe. I think you have, I mentioned it before, we're at peak corporate buyback in mid-June.

17:18You have yourself a little over a week because then you run into real strong seasonality strength in July. The 15 best days for the market since the inception of markets. So if we're going to see this weakness and we're going to see weakness in Meta and NVIDIA, you literally have a week or so to really absorb that weakness. So don't be too cute if you're looking for bargains. Yeah, I totally agree with the seasonality. And that's one of these dynamics that I think, especially with the Fed out of the way. And I would argue that the Fed's a non-factor until December. I mean, they could go in September, but the Fed's out of the way.

17:54And so with earnings kind of coming a couple of weeks away, you do have different periods where markets can just focus on where there are flows and passive flows that want to take this thing higher. I do think that when you had the kind of move that NVIDIA has had and some of these, I mean, the fact that Micron is treated the way it is when a year ago, if you asked me about Micron, this was a truly commoditized company that was trading six, seven times and people felt like that's where it belonged. So after the kind of move you've had, some of the seasonal stuff, I think, doesn't mean all that much, especially when you consider just how overdone we are to the upside in many people's view.

18:28Again, I think there's so many people that want to own NVIDIA lower that I think there are a handful of places where it would be very well supported. You have a position, right, in NVIDIA still? What are you doing with it, if anything? I will probably add if we do get another 10 percent. I don't think that's outside of the realm of possibility, especially given where sentiment is or how quickly sentiment might change. With that said, I still don't think you have another AI growth story where I have zero concern in the short term. Every time they are presented with a challenge, each and every earnings, they knock the cover off the ball and then raise guidance.

19:06Until I see that reverse, I will continue to look for entry points when I think the panic has started to set in. Coming up, analysts leasing up on Nike, but should you swerve on the swoosh? Wire traders aren't just doing it. That's next. And a pullback in bank stocks. Regulators flagging some major issues for the money center names, why they are sounding the alarm and what the banks need to do to fix it. Don't go anywhere. Fast Money is back in two. This is Fast Money with Melissa Lee. Right here on CNBC.

19:45Welcome back to Fast Money. Nike shares higher after Oppenheimer upgraded the sportswear giant to outperform for market perform. The firm reinstating the athletic wear company as a top mega cap pick saying it is poised for a gradual rebound. While analyst Brian Nagel told me in Squawk on the Street this morning that the market for athletic shoes is expanding, Nike has been lagging competitors like On Holding and Hoka Maker Deckers substantially this year. So do you believe this call? Do you think that this is, you know, worth believing or do you just sell this one? Well, I think the analyst, I think it's it's great to get out there and make a call.

20:18It's great to get out there on a company like this. It's had a big a big pullback. And I respect that. But what I heard from this buy was nothing emphatic. I don't see a catalyst. It trades cheap relative to its historical one point. One point one to the market multiple is something it rarely does. But what I heard is at some point it's going to break out. Like at some point the stock's going to move and blah, blah, blah. And that to me isn't overly compelling, even though I hear you. But I still think that we have headwinds on the consumer. And I still think that the multiple could get cheaper.

20:49And by the way, the market multiple is a little extended. So that's not this. This outperform is not a reason to go out and buy it to me because there is no catalyst to go say other than earnings. They'll tell us something different. I mean, he didn't mention the Olympics. The Olympics have traditionally been a catalyst. But I specifically asked him, I said, what is the context? In the world in which you described where Nike reassurts itself as the leader in athletic wear and athletic shoes, where is Hoka? Where is On in that equation? Do they lose market share to Nike again? And he said, no, they're still there.

21:21It's because the market has expanded because more people are wearing sneakers. Right. Sneakers. Yes. If we were in the U.K., we'd be calling them trainers. Trainers. We'd be calling them trainers. But more people are wearing sneakers now, and they're not winning. To me, this sets up very similarly to Lululemon, right? A very similar thing. A very high-quality company that has really done a great job for years and seemed to have lost its way a little bit, and for the first time started to face some competition in Viore, right, that they hadn't before, and sort of losing its mojo. And to me, the setup is really about an asymmetric risk of expectations aren't that high.

22:03Right. And if if they put up a good quarter, I think the stock will really do well. I think it pops. And I think the I think to the upside, because technicals, it's actually working on on an ascending trend line as well. And if you look at on the bottom there, if you zoomed in on the lower right, that's where you're going to see it. And you talked about it with the Olympics. It's going to be a marketing and branding campaign. There's not going to be Hoka there. There's not going to be Han there. It's going to be all Nike all of the time. So I think you have an opportunity here for Nike. So to the upside, you run into a little resistance, maybe 5%, 10 % higher.

22:39But that's where Tim's talking about. That's the prove me state at that point. Yeah, I've snobbed some shares over the last month or so. Like started to, as you said, and been wrong. Got in a little bit too early and started to average in. But with that said, I'm mixed on the call. I don't think that it's a call to buy shares ahead of earnings. In fact, they've even argued that they expect Nike to guide down and to come in a bit late. Their numbers are a bit lighter than consensus numbers. But over the long term, I do think sentiment has swung so negatively. And taking market share becomes an incrementally tougher game for On and Hoka and all the others.

23:17And great read, shoe dog. This is a company that is committed to marketing spend. Now, that doesn't always translate into additional top line growth, but you are not going to out present the Nike product. And that's worked over the long term. And I think it will continue to work in the long term. All right. There's a lot more fast money to come. Here's what's coming up next. Fed's raising the warning flag as some major money center banks don't make the grade in planning for the worst case scenario. The name's in need of some changes. Next. Plus, another big boom in biotech. Sarepta Therapeutics surging on the latest approval out of the FDA.

Read the full transcript

23:57And the CEO is joining us to lay out what's next for the company. You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.

24:15Welcome back to Fast Money. Banks under pressure today. Goldman Sachs down nearly 2 percent. Bank of America, Citi and JP Morgan also pulling back. The latest move comes after the Fed and the FDIC identified weaknesses in the so-called living wills of these companies. Living wills are plans for banks to unwind themselves if there is a crisis or failure. The news coming ahead of bank stress test results released next Wednesday. Now, I thought this was very interesting. Tim thought this was the snooziest story out there, and Karen thought this was very... Says a lot about us. So is this the reason why they all pulled back?

24:47Yes, it's the reason why they all pulled back. Was it overdone? Absolutely. So I read the letter that they sent to each of those four listed. I think there was maybe another one as well. So I'm like, okay, what are they saying? I read it said, Mr. Diamond. I kind of got a kick out of that, that they send a letter directly to him. So what they were pointing out was that the derivatives book, I guess, and the derivatives books needed more, I guess, more definition, more something. I'm not even quite sure what it needed, as well as how would the European banks deal with. The whole exercise, I actually find if they failed, right, then how are they going to deal with that failure?

25:27But I sort of think of if they failed. We've got bigger problems. We've got really, really gigantic problems. Gigantic problems. They also they have until September, I believe, of this year, September 1st, to put together a plan that will be accepted, hopefully, by next year. So I kind of think this is a whole big giant nothing. It feels like the exercise should be on the part of the U.S. government. How will they bail out the banks if they fail? Because that would actually be what happens if these banks face the failure. But that's right. So that's why the exercise I find kind of. Yeah. Why do you think it's easy?

26:00So the question is, would you rather talk about vols or would you rather talk about living wills for banks? I think this is. So I think it's snoozy because this is not in any way why we are either re-rating banks higher now that some of the pressure might be off of them, to the extent that we are still concerned about commercial real estate or we're still concerned about dynamics out there in terms of capital flight. But when you talk about the money center banks, so the ones we're talking about, I mean, go to Citibank. The story here is about efficiency. The story here is about they just had a services investor day and they talked about services revenue for Citibank has been 90 percent of the revenue growth of this bank since 2021.

26:41It's higher margin. It's higher margin business. Now, you say aren't all revenues at bank services? They're not they're not growing anything. They're not building anything. But but ultimately the core parts of their business that have allowed them to expand that ROIC and the dynamics that I think at Citi are still very good are getting better. And so that's the dynamic. By the way, AI plays. I mean, why shouldn't banks benefit from this, too? So I like Citibank. It's of the money setter banks. I own Bank of America. I own J.P. Morgan. My bigger positions in Citi. Coming up, a huge move in Sarepta Therapeutic.

27:14Shares surging 30 percent after its muscular dystrophy drug gets the green light from the FDA. CEO Doug Ingram will join us next to lay out what it means for patients and what's next for the biotech company. That interview when Fast Money returns. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

27:41Welcome back to Fast Money. Stocks closing out the week with a bit of a whimper. The Dow squeezing out a small gain now on a four-day winning streak while the S &P and Nasdaq both ended slightly in the red as NVIDIA lost some of its recent momentum. Shares of Denmark's Zeeland Pharma jumping to a record high today. The company announcing positive results from its early-stage weight-loss drug study. The company saying the drug may produce similar weight-loss results and a better patient experience. Fewer side effects than GLP-1-based treatments like Ozempic and Wegovi. Meantime, Sarepta Therapeutics surging 30 % today.

28:12The stock hitting its highest level since January 2021. The FDA grantee expanded approval for the company's Duchenne muscular dystrophy gene therapy, paving the way for walking and non-walking patients four years of age and older with a confirmed gene mutation to access the drug. Joining us now in a first on CNBC interview is Sarefta CEO Doug Ingram. Doug, great to have you with us. Thank you very much. Thanks for having me. This expanded label obviously means more sales. Bank of America has already said that at peak sales number, they see it as$4 billion up from$2.5 billion. Does that sound right, an incremental$1.5 billion in sales?

28:50It's an enormous opportunity, and we haven't provided a lot of detail on the peak year sales, but this is a massive opportunity. It's first and foremost a massive opportunity for Duchenne families who are living with life-limiting and life-ending disease and have been waiting a very long time for this moment. It's an enormous opportunity for the field of gene therapy. This is a bellwether for good science. And finally, to your very good point, this is a momentous day for Sarepta, for all of our employees who have fought so hard for this approval, but also for those who've invested in us and have taken the risk of investing on a therapy that might bring a better life to families living with this devastating disease.

29:34Absolutely. I mean, this drug potentially would cover everybody in the United States with Duchenne muscular dystrophy, so a huge step forward, particularly when Pfizer pulled the studies of its drug just a couple weeks ago or so. I'm wondering, though, if the controversy around the approval could actually impact the sales of the drug. If you just follow me, you know, Peter Marks, who is the FDA director of the Center for Biologics Evaluation and Research, overruled three review teams as well as two top lieutenants in order to get this drug across the finish line here, Doug. And some people are saying that perhaps this could impact whether or not payers are willing to pay for this very expensive drug or if it could become the next adjuhelm, which, of course, is a drug that also had a sort of similar controversial approval process.

30:24And ultimately, the payers limited access to this drug and it was discontinued. So a couple thoughts. First, the science that supports this therapy is brilliant. In the words of the decisional memo, which is the FDA memo that supports the therapy, it was compelling. So to anyone who's curious about all of the wealth of evidence that justifies this broad label, I would simply ask them to spend some time looking at the science and understanding the decisional memo. The second thing to know is that the opportunity itself is massive, both to help patients. Your point, this is a very broad label that can help the vast majority of patients with Duchenne muscular dystrophy in their families.

31:06And then the third question, of course, the third big issue is whether we can execute. And the short answer is that there is undoubtedly, and I don't think there are many people who will disagree with it. There is really no organization better prepared to execute and make this therapy a success than Sarepta. I would remind folks that we have been doing this for a very long time. We've been serving the Duchenne community for many years. This is our fourth therapy. We've grown, if we're going to focus on revenue, as a market for the success that we've had. We've grown since the beginning of 2017 at a compound annual growth rate of about 115%.

31:42We launched this therapy in a very narrow group of patients, just for a five-year-old, very, very narrow, last June. And in the first six months of launch, we did$200 million. We served that community brilliantly. In fact, we almost doubled all of the other gene therapy revenue in that same period that had been approved in the last few years combined. So we're well prepared to execute. And we have a great relationship with payers. We've had great conversations with payers. And they've actually done a very nice job of giving these kids access as they need since this disease is killing them. Yeah.

32:26And you made that point clear on the conference call that you held this morning with analysts that your company is ready for this commercial launch. There's many infusion sites that are ready to go. you've manufactured the drug, et cetera, and that you'd have no need right now to raise any more funds. But a 30 percent pop in the stock seems like a great opportunity, Doug. You know, we said today on the call, the classic biotech playbook is you get a pop like this, then you use it as the basis for a reason. So the reason that people do that, the reason biotechs do that is biotechs typically need money.

33:00They are usually, most of them are in a stage where they're not profitable. We're in a rarefied position. We are a profitable organization already, both on a non-gap basis and often on a gap basis. We'll be cash flow positive in the next couple of quarters. We have very robust revenue. We have a lot of cash on our balance sheet, and we simply don't need to raise money right now. We're really just focusing on deploying the resources that we have right now and making sure that this launch is maximally successful. We feel an enormous amount of opportunity here, but we feel an enormous obligation to these patients to get this right.

33:40Doug, thank you so much for telling us about the drug and the approval process. Doug Ingram, the CEO of Sarepta Therapeutics, again, up 30 percent on this groundbreaking approval here. What do we make of a stock like this? Well, it's interesting if you look at the move in the stock, so move 30 percent. If you look at the analyst community and how they follow through. And again, whether it was what Doug said or whether it's what everyone has noted is that the FDA tenor was about as strong as you could have in terms of what they said. So the analyst community, in many cases, you know, I see JP Morgan upgraded.

34:09They're targeted by about 15 percent. TD by 20. Cantor, zero. Piper, zero. So the question is really, what do you do with this kind of a move when the stock has responded? And but what is Doug pointed out, this is a company that on 25 numbers, at least if I'm looking at TD's account, TD's report, that they're going to be, you know, make 10 bucks a share by 25 and that this is, you know, 17 times. So you can do that math and it's a pretty interesting dynamic. But has the stock priced a lot in? We've got a news alert here on the CDK hack. Deidre Bosa's got all the details. Deidre. Hey, Melissa, that's right.

34:44Great new details in that hack that is affecting thousands of car dealerships across North America. Bloomberg is reporting this according to a person familiar that a group that claims to have hacked CDK Global, that's a software provider to those car dealerships, has demanded tens of millions of dollars in ransom. Bloomberg also reports that CDK is planning to make the payment according to that source familiar. also adds that in the early days of any ransomware attack, discussions are fluid and the situation could change at any time. But that is the latest, Melissa, and that massive CDK hack. We now know, according to Bloomberg, that it's ransomware.

35:22All right. Deirdre, thank you. Deirdre Bosa. Coming up, a rough week in crypto where Bitcoin could be heading and how the proxy players are holding up. That's next. Fast Money's back in two.

35:40Welcome back to Fast Money. Time for our chart of the week. That is week with an A. Bitcoin under pressure down 2 % this week and nearly 9 % since early June. The crypto now at its lowest level in more than a month and posting its second straight weekly loss. Crypto proxies, Coinbase, Marathon Digital, Riot platforms all seeing steep losses today in sympathy. Grasa, what did you make of this move? So after the halving, the miners are going to be under pressure. They have to be more efficient. They're only getting half the half the amount of pay for the same amount of work that they were doing before.

36:12So I think that's where it started. Also, you had Gensler coming out with the Ethereum approval for ETH and pushing it, pushing it to the end of summer. I think people thought it was going to be coming sooner. I think it was going to be people thought it was going to be coming around June. So you have Ibit, which was the ETF for Bitcoin. A lot of people wound up buying it. And you're leveling off here. I think it's all pretty much expected. I think you'll wind up seeing these all round on the bottom here and wind up ticking higher. You're still in Ether? I still am. And I bet. You're still in Coinbase?

36:44Still in Coinbase on some Ether. It's interesting how Ether is outperforming here. And again, my view is that you're seeing broadening in the sector. And so that's been an argument for the on-ramp. But with Coinbase, you've heard me say that a thousand times. So I'll just point out that what you have seen across the spectrum this week is that there are other tokens that are actually rallying. And I think as long as we have the market froth that we talked about, I think they're going higher. You would think that, well, you would think that when the markets were in better shape even earlier this week, that Bitcoin would be performing a little bit better.

37:20Yeah, I don't know why that is exactly. I don't know if it's that inflation's coming down or if that was sort of the sort of tough talk from the Fed, from Jay Powell. I don't know. It didn't seem to me to be panicky or super heavy. I don't know what to make of it, though, why it was trading down. Coming up, some big names on deck to report results next week. So we are playing our favorite game, an actual game, not a made-up game that Grasa likes to play. To see how the traders are positioning ahead of earnings, trade it or fade it, it is up next for Fast Money in 2.

38:01Welcome back to Fast Money. Some big names ready to report earnings next week. Carnival, FedEx, Micron, and more all on deck. So how should you play these names ahead of the numbers? Let's find out with a good old game of... Trade it or bait it! That's right. America's favorite game. America's favorite game. It is America's favorite game. Not Steve Grosso's game. It's America's favorite game. We kick it off here with Micron. Results due out Wednesday. Shares up 63 % this year. Steve. Mole. I would trade this one. It can't be factored in. You need for AI, you need DRAM. And DRAM is over 70 % of their revenues.

38:41I think we're just at the beginning stages of this story. People didn't come around to knowing that Micron was even an AI name. Now they are. So I think it can't be over yet. Trade it. All right, Tim, what do you think? Yeah, I'm going to fade it. I get it. And the question is often is what's the multiple you want to pay for this stock? And if you read the analysts, you know, it's near term conditions, but it's also a combination of they think EPS is going higher and that actually you're getting 20 bucks at EPS somehow by next year. But if you put a 10 times multiple on it, you can get to a big number.

39:12I'm not sure you're supposed to do that. I think it's overdone in the short term. And again, once commoditized, why doesn't the same stuff become somewhat commoditized? I don't want to put that multiple on it. Karen, what do you think? I mean, first of all, I'm proud with the definition of the game. Trade it. Trade it really means do you want to – that generally means sell it. You get rid of it. Yes. But for this game, which trade it means buy it, I would actually because I do think – I know this used to be a very cyclical business and still is and that multiples used to reflect that. One day they still will, but I think we're still at the part where earnings go up a lot.

39:43and the multiple actually hangs in there. So trade it. All right. Up next, FedEx reporting Tuesday. Shares virtually flat for the year. Bonoan. I'm fading this one, or maybe I'm trading it according to Karen's definition, but I'm selling it. Okay. I'm not buying it. Listen, I think that a lot of the positive catalyst for the stock has come from cost cutting, and I don't think that's a long-term strategy. You can't cost cut your way to profitability or earnings growth, and I won't be deploying capital for that reason. Karen? I found they actually did cost cut their way to some growth or less bad, actually.

40:21But I do think also I've looked at this company for several years. 14 times earnings seems to kind of be the bottom. You know what? That's just a big enough discount to the market where I would trade it, I guess. So, yes, trade it. Yes. All right. And finally, Carnival, the cruise line stock is down 14 percent so far this year. Steve? Revenues at record levels. Free cash flow are near record levels. They've already recouped everything after the pandemic. Remember, this was one of the businesses that was taken down to a zero during COVID. So they had a lot to recapture. They've recaptured a lot.

41:00Everyone's always worried about debt with this one. But I think when people are looking about vacations, it's still probably the most efficient vacation you could possibly do. You get on a ship, plug and play. I know people hate it. It's binary, but I'm going to go with trade it. Bono in. I tend to agree with a lot of it. Listen, they have added a lot of leverage to that balance sheet. But to Steve's point, they have been able to turn around that free cash flow and operating income story, which lets you either delever the company or operate as a going concern with higher leverage. I think they've been executing on that.

41:31And I'm actually glad that this thing is pulled back because it had quite a run prior to that sell-off. Yeah, look, the next cruise I go on will be my first, as Guy likes to say. and I don't know if guys have taken a cruise, but I've never taken one and I doubt I'm going to take one, but you never know. But I think what these guys are doing is they continue to beat and raise and that's the dynamic that these guys are talking about as well. I think the leverage issue is overdone given where they have actually seen pricing power and they've been starting to pay some of that down. I think they're going to beat and raise here.

42:00All right. Up next, Mind the Trade.

42:14Time for the final trade. Tim Seymour. Yeah, I think XLE is bouncing with oil prices that have been rallying, even in the face of a higher dollar energy. Karen Feinerman. Yeah, so I don't really love to go against Carter because I do like his work. But Metta, I really like. If I own none, I would absolutely get started here, for sure. Bonoan. I think that Nike will find a way to just do it, so I'm sticking with it. See? So we had that great interview with Sarepta, and it made me think about what their headwind was. It was drug manufacturing. They use Catalan. Catalan's biggest customer is Sarepta.

42:51Final trade, Catalan. Interesting. Thank you for watching Fast Money. Have a terrific weekend. We'll see you back here on Monday at 5. Meantime, don't go anywhere. Mad Money with Jim Cramer starts right now.

43:04All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:38To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.

From the publisher

Has the fever broken for the high momentum stocks? Nvidia running out of steam this week, as some other high fliers also pull back. Is this just a bump in the road or the beginning of a summer slowdown? Plus Sarepta’s big surge. The biotech company getting expanded approval from the FDA for its muscular dystrophy drug. What the CEO says is next for the company.

 

Fast Money Disclaimer

 


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Fever Breaking For Momentum Stocks… And Sarepta Surges After FDA Approval 6/21/24CNBC's "Fast Money" · 44 min
Listen in VO